September 2025
1. KOBAYASHI S, Nakachi K, Yamamoto K, Ueno M, et al
   Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B).
   J Gastroenterol. 2025 Sep 6. doi: 10.1007/s00535-025-02294.
   

   >> Share

   
   June 2025
2. NAITOH I, Isayama H, Akamatsu N, Mizuno S, et al
   The 2024 diagnostic criteria for primary sclerosing cholangitis.
   J Gastroenterol. 2025 Jun 12. doi: 10.1007/s00535-025-02265.
   

   >> Share

   
   May 2025
3. ZHU J, Chen H, Meng L, Jiang J, et al
   Serum FGF19 combined with GGT and other biomarkers predicted native liver survival following Kasai portoenterostomy in early biliary atresia.
   J Gastroenterol. 2025 May 5. doi: 10.1007/s00535-025-02234.
   

   >> Share

   
   April 2025
4. YOSHIDA M, Toyohara T, Hori Y, Kato A, et al
   Endoscopic liquid biopsy of bile: superior diagnostic and prognostic performance of bile-derived exosomal miR-21-5p for biliary tract cancers.
   J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02250.
   

   >> Share

   
   February 2025
5. HAO Z, Lu Y, Hao Y, Luo Y, et al
   Correction: Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
   J Gastroenterol. 2025 Feb 27. doi: 10.1007/s00535-025-02217.
   

   >> Share

   
   
6. TANAKA A, Notohara K, Tobari M, Abe M, et al
   A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
   J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
   

   >> Share

   
   November 2024
7. HAO Z, Lu Y, Hao Y, Luo Y, et al
   Fungal mycobiome dysbiosis in choledocholithiasis concurrent with cholangitis.
   J Gastroenterol. 2024 Nov 27. doi: 10.1007/s00535-024-02183.
   

   >> Share

   
   
8. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
   Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
   J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
   

   >> Share

   
   
9. CAO Z, Yang Y, Liu S, Sun L, et al
   FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
   J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
   

   >> Share

   
   August 2024
10. TAKAOKA S, Hamada T, Nakai Y, Yasunaga H, et al
    Response to the letter by Buldukoglu et al. regarding our manuscript "Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation".
    J Gastroenterol. 2024 Aug 6. doi: 10.1007/s00535-024-02143.
    

    >> Share

    
    July 2024
11. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    

    >> Share

    
    June 2024
12. TAKAOKA S, Hamada T, Takahara N, Fukuda R, et al
    Body mass index and survival among patients with advanced biliary tract cancer: a single-institutional study with nationwide data-based validation.
    J Gastroenterol. 2024 Jun 19. doi: 10.1007/s00535-024-02124.
    

    >> Share

    
    May 2024
13. KANO Y, Ishikawa T, Yamao K, Mizutani Y, et al
    What is the appropriate method of pathological specimen collection for cholangiocarcinoma detection in primary sclerosing cholangitis?
    J Gastroenterol. 2024 May 7. doi: 10.1007/s00535-024-02105.
    

    >> Share

    
    March 2024
14. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    

    >> Share

    
    October 2023
15. WU JF, Peng SS, Tai CS, Lin WH, et al
    The magnetic resonance imaging and age-adjusted matrix metalloproteinase-7 assist the diagnosis of biliary atresia.
    J Gastroenterol. 2023 Oct 30. doi: 10.1007/s00535-023-02051.
    

    >> Share

    
    
16. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    

    >> Share

    
    September 2023
17. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    

    >> Share

    
    July 2023
18. FUJITA N, Yasuda I, Endo I, Isayama H, et al
    Evidence-based clinical practice guidelines for cholelithiasis 2021.
    J Gastroenterol. 2023 Jul 15. doi: 10.1007/s00535-023-02014.
    

    >> Share

    
    
19. PENG M, Li H, Cao H, Huang Y, et al
    Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2023 Jul 11. doi: 10.1007/s00535-023-02012.
    

    >> Share

    
    June 2023
20. XU H, Lin X, Li Z, He X, et al
    VIRMA facilitates intrahepatic cholangiocarcinoma progression through epigenetic augmentation of TMED2 and PARD3B mRNA stabilization.
    J Gastroenterol. 2023 Jun 30. doi: 10.1007/s00535-023-02015.
    

    >> Share

    
    
21. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    

    >> Share

    
    May 2023
22. KIM KA, Choi HY, Ki M, Jang ES, et al
    Epidemiological trends and outcomes of primary biliary cholangitis in South Korea between 2009 and 2019.
    J Gastroenterol. 2023 May 17. doi: 10.1007/s00535-023-01999.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share